Elmind Capital LP Acquires Shares of 15,000 United Therapeutics Corporation $UTHR

Elmind Capital LP bought a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 2nd quarter, HoldingsChannel.com reports. The institutional investor bought 15,000 shares of the biotechnology company’s stock, valued at approximately $8,127,450,000. United Therapeutics accounts for about 2.0% of Elmind Capital LP’s holdings, making the stock its 16th largest position.

A number of other hedge funds have also modified their holdings of the business. Callan Family Office LLC acquired a new position in United Therapeutics during the second quarter worth about $1,217,000. Leuthold Group LLC lifted its stake in United Therapeutics by 41.4% in the 4th quarter. Leuthold Group LLC now owns 10,672 shares of the biotechnology company’s stock worth $5,200,000 after purchasing an additional 3,126 shares in the last quarter. UBS Group AG lifted its stake in United Therapeutics by 45.3% in the 4th quarter. UBS Group AG now owns 225,849 shares of the biotechnology company’s stock worth $110,045,000 after purchasing an additional 70,445 shares in the last quarter. Nicholas Investment Partners LP boosted its holdings in shares of United Therapeutics by 478.5% during the 4th quarter. Nicholas Investment Partners LP now owns 4,553 shares of the biotechnology company’s stock worth $2,218,000 after purchasing an additional 3,766 shares during the last quarter. Finally, M&T Bank Corp boosted its holdings in shares of United Therapeutics by 171.6% during the 4th quarter. M&T Bank Corp now owns 3,142 shares of the biotechnology company’s stock worth $1,531,000 after purchasing an additional 1,985 shares during the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

United Therapeutics Stock Performance

UTHR opened at $518.53 on Wednesday. United Therapeutics Corporation has a one year low of $302.19 and a one year high of $609.35. The stock has a market capitalization of $22.24 billion, a PE ratio of 18.55, a P/E/G ratio of 1.74 and a beta of 0.59. The business’s 50 day moving average price is $531.75 and its 200 day moving average price is $538.30.

United Therapeutics (NASDAQ:UTHR) last issued its quarterly earnings data on Wednesday, August 5th. The biotechnology company reported $7.27 earnings per share for the quarter, topping the consensus estimate of $6.86 by $0.41. The company had revenue of $783.30 million during the quarter, compared to analyst estimates of $804.65 million. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. During the same period in the prior year, the business posted $6.41 earnings per share. As a group, equities research analysts forecast that United Therapeutics Corporation will post 26.33 earnings per share for the current fiscal year.

Insider Buying and Selling at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, June 4th. The stock was sold at an average price of $546.28, for a total transaction of $5,462,800.00. Following the completion of the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,311,581.28. This represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CEO Martine A. Rothblatt sold 9,500 shares of the firm’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $545.83, for a total value of $5,185,385.00. Following the sale, the chief executive officer directly owned 40,513 shares of the company’s stock, valued at $22,113,210.79. The trade was a 19.00% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 434,075 shares of company stock worth $233,340,010. Corporate insiders own 8.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a report on Thursday, May 21st. Weiss Ratings raised United Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, August 13th. JPMorgan Chase & Co. raised their target price on United Therapeutics from $685.00 to $687.00 and gave the stock an “overweight” rating in a research note on Thursday, July 23rd. Royal Bank Of Canada reduced their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, Bank of America lowered their price target on shares of United Therapeutics from $620.00 to $613.00 and set a “neutral” rating on the stock in a research report on Friday, July 10th. Eleven investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat, United Therapeutics has an average rating of “Moderate Buy” and an average target price of $646.00.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.